Therapeutic potential of anticancer immunotoxins
Authors:
- Swati ChoudharySCSwati Choudhary
- Mrudula MathewMMMrudula Mathew
- Rama S. VermaRVRama S. Verma
- 1 June 2011
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 16 (11-12) , 495-503
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Targeted Toxins in Brain Tumor TherapyToxins, 2010
- Toxin-Based Therapeutic ApproachesToxins, 2010
- Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical TrialClinical Cancer Research, 2010
- A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast CarcinomaClinical Cancer Research, 2009
- Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1PClinical Cancer Research, 2009
- Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell LeukemiaJournal of Clinical Oncology, 2009
- A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicityBlood, 2009
- An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopesProceedings of the National Academy of Sciences, 2008
- The Contributions of Paul Ehrlich to Pharmacology: A Tribute on the Occasion of the Centenary of His Nobel PrizePharmacology, 2008
- Mutations in Diphtheria Toxin Separate Binding from Entry and Amplify Immunotoxin SelectivityScience, 1987